Technology | March 25, 2011

Galectin-3 Testing Service Launch to Assess Heart Failure Patients

Galectin-3 is a mediator of cardiac fibrosis (pictured) and adverse remodeling in heart failure patients.

March 25, 2011 – A new galectin-3 test, recently cleared by the U.S. Food and Drug Administration (FDA) to help assess the prognosis of patients with chronic heart failure, is now offered by Health Diagnostic Laboratory (HDL). BG Medicine Inc. announced the agreement under which HDL will offer galectin-3 testing services based on the BG Medicine Galectin-3 Test.

Elevated galectin-3 levels are associated with an inherently progressive form of heart failure that is associated with an increased risk of hospitalization or death. Galectin-3 has been implicated in a variety of biological processes important in heart failure development and progression, including fibrosis. Progressive cardiac fibrosis interferes with the cardiac pump function and increases the risk of death.

"HDL Inc. is providing a new model of laboratory testing services to over 5,000 physicians with an emphasis on markers related to cardiovascular disease," said Pieter Muntendam, M.D., president and CEO of BG Medicine. "The cardiovascular focus of HDL, Inc. makes this an excellent partnership to bring our message of the importance of galectin-3 in cardiac disease to the growing number physicians served by HDL Inc."

"Galectin-3 further enhances our extensive cardiovascular disease offering," said Tonya Mallory, CEO and co-founder of HDL Inc. "Novel markers like galectin-3 are expected to enable a new medical model where physicians can triage patients not only based on their clinical status on the day of the visit, but also based on the type of underlying disease process and its prognostic implications."

For more information: www.myhdl.com, www.galectin-3.com

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init